Endo International, with its U.S. headquarters in Malvern, is entering late-stage testing of one of its products for cellulite treatment, writes John George for the Philadelphia Business Journal.

Cellulite causes a localized alteration in the skin contours that affect more than 85 percent of women. The American Society for Aesthetic Plastic Surgery estimates that women spend around $3 billion a year on anti-cellulite treatments, mostly on over-the-counter products. This makes the potential market for an FDA-approved product huge.

“Despite the number of options, there still are no U.S. Food and Drug Administration-approved pharmacologic treatments, and patients continue to seek new, effective, non-surgical treatment options,” said Dr. Matthew W. Davis, Endo’s chief medical officer and senior vice president for research and development.

[uam_ad id=”71803″]

Advertisement

The company has entered Phase-III clinical trials, usually the last step before seeking FDA approval. It will enroll 840 women aged 18 or older with moderate or severe cellulite. They will participate in three treatments, receiving either the therapy or a placebo.

“This is an important step in our goal to provide a new treatment option for appropriate patients with cellulite,” said Davis.

Read more about the potential treatment in the Philadelphia Business Journal here, and check out previous VISTA Today coverage of Endo here.

[uam_ad id=”58462″]